Weight-Loss drug semaglutide takes on atrial fibrillation in new trial

NCT ID NCT06499857

Recruiting now Disease control Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether semaglutide, a medication used for weight loss, can help control atrial fibrillation (AFib) in people who are overweight or have obesity. About 200 adults aged 18-75 with AFib and a BMI of 30 or higher will receive semaglutide plus standard AFib care. Researchers will monitor how long it takes for AFib to return and how much time participants spend in AFib, along with changes in weight and heart fat.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION OVERWEIGHT OR OBESITY

Contacts and locations

Locations

The University of Arizona College of Medicine- Phoenix
NOT_YET_RECRUITING

Phoenix, Arizona, 85004, United States
University of Chicago
RECRUITING

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.